Figure 4
From: Identification of a cholesterol metabolism-related prognostic signature for multiple myeloma

Integrated analysis of prognostic signature and clinicopathologic factors. Comparison of normalized CMI according to (A) number of transplants, (B) International Staging System (ISS), (C) revised-ISS (R-ISS), (D) albumin levels, (E) beta-2 microglobulin (β2M) levels and (F) lactate dehydrogenase (LDH) levels. (G) Evaluations of the drug susceptibility between high- and low-CMI groups in the GSE136324 dataset. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.